Compare EML & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EML | ACHV |
|---|---|---|
| Founded | 1858 | N/A |
| Country | United States | United States |
| Employees | N/A | 28 |
| Industry | Industrial Machinery/Components | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 119.2M | 172.0M |
| IPO Year | 1995 | 2018 |
| Metric | EML | ACHV |
|---|---|---|
| Price | $20.86 | $3.20 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $15.50 |
| AVG Volume (30 Days) | 15.3K | ★ 773.9K |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | ★ 2.11% | N/A |
| EPS Growth | ★ 185.40 | N/A |
| EPS | ★ 1.17 | N/A |
| Revenue | ★ $248,970,345.00 | N/A |
| Revenue This Year | $19.05 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $17.83 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $17.61 | $1.84 |
| 52 Week High | $26.76 | $6.03 |
| Indicator | EML | ACHV |
|---|---|---|
| Relative Strength Index (RSI) | 59.74 | 39.09 |
| Support Level | $18.85 | $3.03 |
| Resistance Level | $21.17 | $3.39 |
| Average True Range (ATR) | 0.55 | 0.27 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 66.67 | 34.85 |
The Eastern Co manages industrial businesses that design, manufacture, and sell engineered solutions to industrial markets. The company manages the financial, operational, and strategic performance of its businesses to increase cash generation, operating earnings, and long-term shareholder value. It operates in the United States and Other Countries and generates the majority of its revenue from the United States.
Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.